{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:56:46Z","timestamp":1781647006591,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA289547"],"award-info":[{"award-number":["R01CA289547"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA289547"],"award-info":[{"award-number":["R01CA289547"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In the era of precision oncology, patients with advanced cancer are often living longer but are enduring years of fatiguing treatment. Fatigue is among the most common, chronic, and under-addressed side effects of advanced cancer treatment, and can lead to dose reductions, treatment interruptions, and discontinuation. Oral PolyADP-ribose polymerase (PARP) inhibitors have revolutionized the treatment of advanced ovarian cancer but are often accompanied by clinically-significant fatigue, and evidence-based treatments to cope with this side effect remain limited. A pilot trial suggests that telehealth acceptance and commitment therapy (ACT), a variant of cognitive behavioral therapy based on acceptance, mindfulness, and personal values, has potential to improve fatigue interference (i.e. disrupting activity and quality of life) among ovarian cancer patients on maintenance PARP inhibitors. This study protocol describes a fully-powered randomized controlled trial (RCT) of an innovative, remotely-delivered ACT intervention (\u2018\n                      <jats:italic>REVITALIZE<\/jats:italic>\n                      \u2019) that aims to improve fatigue outcomes and PARP inhibitor adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This two-armed, prospective RCT randomizes 240 adults with advanced ovarian cancer who report moderate to severe fatigue while on PARP inhibitors 1:1 to either\n                      <jats:italic>REVITALIZE<\/jats:italic>\n                      or education-enhanced usual care. The\n                      <jats:italic>REVITALIZE<\/jats:italic>\n                      intervention includes eight weekly one-hour individual sessions delivered via videoconference, plus two booster sessions at one- and two-month intervals thereafter. Participants, recruited from both academic and community cancer care sites across three U.S. regions, will complete assessments at baseline, mid-intervention, post-intervention, and 20 and 28-week follow-up (FU). The primary patient-reported outcome is change in fatigue interference from baseline to week 20 (FU1). Secondary patient-reported outcomes include fatigue severity, catastrophizing, self-efficacy, and quality of life. The primary behavioral outcome is monthly PARP inhibitor adherence, assessed by wireless medication adherence monitors; dose interruptions, reductions, and persistence will also be evaluated using adherence monitors and medical chart review.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      This paper describes a RCT that will evaluate the efficacy of the telehealth\n                      <jats:italic>REVITALIZE<\/jats:italic>\n                      intervention for improving fatigue-related outcomes and medication adherence among adults with advanced ovarian cancer taking PARP inhibitors. Findings will inform clinical practice and supportive care for adults with advanced ovarian cancer receiving treatments that cause fatigue.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov NCT06710548 on November 29, 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15936-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:25:00Z","timestamp":1775129100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention (\u2018REVITALIZE\u2019) to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol"],"prefix":"10.1186","volume":"26","author":[{"given":"Joanna J.","family":"Arch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Poort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Slivjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline S.","family":"Nealis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Genung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Andorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Mazina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page","family":"Widick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Lefkowits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"15936_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2019.06.012","volume":"141","author":"VC Ruiz-Schutz","year":"2019","unstructured":"Ruiz-Schutz VC, Gomes LM, Mariano RC, de Almeida DVP, Pimenta JM, Dal Molin GZ, Kater FR, Yamamura R, Correa Neto NF, Maluf FC, et al. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2019;141:163\u201373.","journal-title":"Crit Rev Oncol Hematol"},{"key":"15936_CR2","doi-asserted-by":"crossref","unstructured":"Martorana F, Da Silva LA, Sessa C, Colombo I. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers (Basel). 2022;14(4):953.","DOI":"10.3390\/cancers14040953"},{"issue":"9","key":"15936_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"X Zhou","year":"2021","unstructured":"Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, Zhang X, Xu J, Fei K, Zhang Z, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265\u201374.","journal-title":"Lancet Oncol"},{"key":"15936_CR4","doi-asserted-by":"crossref","unstructured":"Poort H, Peters M, Bleijenberg G, Gielissen MF, Goedendorp MM, Jacobsen P, Verhagen S, Knoop H. Psychosocial interventions for fatigue during cancer treatment with palliative intent. Cochrane Database Syst Rev. 2017(7):1\u201362.","DOI":"10.1002\/14651858.CD012030.pub2"},{"issue":"17","key":"15936_CR5","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1200\/JCO.2013.53.4495","volume":"32","author":"JE Bower","year":"2014","unstructured":"Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32(17):1840\u201350.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15936_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, Nagao S, Vergote I, Colombo N, M\u00e4enp\u00e4\u00e4 J. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392.","journal-title":"Ann Oncol"},{"issue":"5","key":"15936_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437\u201348.","journal-title":"N Engl J Med"},{"issue":"23","key":"15936_CR8","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, Lee J-Y, Moroney JW, Colombo N, Roszak A. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162\u201374.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"15936_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","volume":"12","author":"M Hofman","year":"2007","unstructured":"Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4\u201310.","journal-title":"Oncologist"},{"issue":"18","key":"15936_CR10","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1200\/JCO.2013.54.4346","volume":"32","author":"A Spathis","year":"2014","unstructured":"Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, O\u2019Brien M, Stone P, Benepal T, Bates N, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32(18):1882\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"15936_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.2014.55.8353","volume":"32","author":"KJ Ruddy","year":"2014","unstructured":"Ruddy KJ, Barton D, Loprinzi CL. Laying to rest psychostimulants for cancer-related fatigue? J Clin Oncol. 2014;32(18):1865\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15936_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","volume":"3","author":"KM Mustian","year":"2017","unstructured":"Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"15936_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/JCO.24.00965","volume":"43","author":"CE Mosher","year":"2025","unstructured":"Mosher CE, Lee S, Addington EL, Park S, Lewson AB, Snyder S, Hirsh AT, Bricker JB, Miller KD, Ballinger TJ. Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer. J Clin Oncol. 2025;43(6):662\u201371.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15936_CR14","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"15936_CR15","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"15936_CR16","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"15936_CR17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"3","key":"15936_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41(3):609\u201317.","journal-title":"J Clin Oncol"},{"key":"15936_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2019.06.012","volume":"141","author":"VC Ruiz-Schutz","year":"2019","unstructured":"Ruiz-Schutz VC, Gomes LM, Mariano RC, de Almeida DV, Pimenta JM, Dal Molin GZ, Kater FR, Yamamura R, Neto NFC, Maluf FC. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials. Crit Rev Oncol\/Hematol. 2019;141:163\u201373.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"15936_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ygyno.2020.10.034","volume":"160","author":"H Poort","year":"2021","unstructured":"Poort H, Fenton AT, Thompson E, Dinardo MM, Liu JF, Arch JJ, Wright AA. Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecol Oncol. 2021;160(1):227\u201333.","journal-title":"Gynecol Oncol"},{"key":"15936_CR21","doi-asserted-by":"publisher","first-page":"106168","DOI":"10.1016\/j.cct.2020.106168","volume":"98","author":"CE Mosher","year":"2020","unstructured":"Mosher CE, Krueger E, Hirsh AT, Miller KD, Ballinger TJ, Storniolo AM, Schneider BP, Newton EV, Champion VL, Johns SA. Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer. Contemp Clin Trials. 2020;98:106168.","journal-title":"Contemp Clin Trials"},{"key":"15936_CR22","volume-title":"Acceptance and Commitment Therapy: An experiential approach to behavior change","author":"SC Hayes","year":"1999","unstructured":"Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: An experiential approach to behavior change. New York, NY: Guilford Press; 1999."},{"key":"15936_CR23","doi-asserted-by":"publisher","DOI":"10.1037\/17335-000","volume-title":"Acceptance and Commitment Therapy: The process and practice of mindful change","author":"SC Hayes","year":"2012","unstructured":"Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: The process and practice of mindful change. 2nd ed. New York, NY: Guilford Press; 2012.","edition":"2"},{"issue":"2","key":"15936_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/0011000012461955","volume":"41","author":"JE Angiola","year":"2013","unstructured":"Angiola JE, Bowen AM. Quality of life in advanced cancer: An acceptance and commitment therapy view. Couns Psychol. 2013;41(2):313\u201335.","journal-title":"Couns Psychol"},{"issue":"1","key":"15936_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12904-022-01087-z","volume":"21","author":"JJ Arch","year":"2022","unstructured":"Arch JJ, Mitchell JL, Schmiege SJ, Levin ME, Genung SR, Nealis MS, Fink RM, Bright E, Andorsky DJ, Kutner JS. A randomized controlled trial of a multi-modal palliative care intervention to promote advance care planning and psychological well-being among adults with advanced cancer: study protocol. BMC Palliat Care. 2022;21(1):1\u201313.","journal-title":"BMC Palliat Care"},{"key":"15936_CR26","volume-title":"Mastery of your anxiety and panic: Therapist guide","author":"MG Craske","year":"2007","unstructured":"Craske MG, Barlow DH. Mastery of your anxiety and panic: Therapist guide. 4th ed. New York, NY: Oxford University Press; 2007.","edition":"4"},{"key":"15936_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ygyno.2023.08.020","volume":"177","author":"AA Wright","year":"2023","unstructured":"Wright AA, Poort H, Tavormina A, Schmiege SJ, Matulonis UA, Campos SM, Liu JF, Slivjak ET, Gilmour AL, Salinger JM, et al. Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue. Gynecol Oncol. 2023;177:165\u201372.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"15936_CR28","first-page":"169","volume":"19","author":"KA Donovan","year":"2010","unstructured":"Donovan KA, Jacobsen PB. The Fatigue Symptom Inventory: a systematic review of its psychometric properties. Supportive Cancer Care. 2010;19(2):169\u201385.","journal-title":"Supportive Cancer Care"},{"issue":"4","key":"15936_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1023\/A:1008842517972","volume":"7","author":"DM Hann","year":"1998","unstructured":"Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, Greenberg H, Lyman G. Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998;7(4):301\u201310.","journal-title":"Qual Life Res"},{"key":"15936_CR30","unstructured":"National Cancer Institute. Life after cancer treatment: Facing forward. National Cancer Institute; 2019."},{"key":"15936_CR31","unstructured":"R Core Team: R: A language and environment for statistical computing. In, Vienna. Austria: R Foundation for Statistical Computing; 2024."},{"issue":"2","key":"15936_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"15936_CR33","unstructured":"Wisepill. Providing real-time medication adherence solutions for over 10 years [https:\/\/www.wisepill.com\/]."},{"issue":"6","key":"15936_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201356.","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"15936_CR35","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/abm\/kaab118","volume":"56","author":"JJ Arch","year":"2022","unstructured":"Arch JJ, Crespi CM, Levin ME, Genung SR, Nealis M, Mitchell JL, Bright EE, Albright K, Magidson JF, Stanton AL. Randomized controlled pilot trial of a low-touch remotely-delivered values intervention to promote adherence to adjuvant endocrine therapy among breast cancer survivors. Ann Behav Med. 2022;56(8):856\u201371.","journal-title":"Ann Behav Med"},{"issue":"4","key":"15936_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1037\/ccp0000630","volume":"89","author":"JJ Arch","year":"2021","unstructured":"Arch JJ, Mitchell JL, Genung SR, Judd CM, Andorsky DJ, Bricker JB, Stanton AL. Randomized trial of an Acceptance and Commitment Therapy intervention for anxious cancer survivors in community clinics: Outcomes and moderators. J Consult Clin Psychol. 2021;89(4):327\u201340.","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"15936_CR37","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/pon.3890","volume":"25","author":"JJ Arch","year":"2016","unstructured":"Arch JJ, Mitchell J. An acceptance and commitment therapy group intervention for cancer survivors experiencing anxiety at reentry. Psycho-oncology. 2016;25(5):610\u20135.","journal-title":"Psycho-oncology"},{"issue":"10","key":"15936_CR38","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1089\/jpm.2019.0398","volume":"23","author":"JJ Arch","year":"2020","unstructured":"Arch JJ, Fishbein JN, Ferris MC, Mitchell JL, Levin ME, Slivjak ET, Andorsky DJ, Kutner JS. Acceptability, feasibility, and potential for efficacy of an acceptance-based intervention to address psychosocial and advance care planning needs among anxious and depressed adults with metastatic cancer. J Palliat Med. 2020;23(10):1380\u20135.","journal-title":"J Palliat Med"},{"issue":"5","key":"15936_CR39","first-page":"1591","volume":"27","author":"JJ Arch","year":"2019","unstructured":"Arch JJ, Stanton AL. Examining the usual in usual care: a critical review and recommendations for usual care conditions in psycho-oncology. Support Care Cancer. 2019;27(5):1591\u2013600.","journal-title":"Support Care Cancer"},{"issue":"6","key":"15936_CR40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1037\/0022-006X.72.6.1050","volume":"72","author":"WR Miller","year":"2004","unstructured":"Miller WR, Yahne CE, Moyers TB, Martinez J, Pirritano M. A randomized trial of methods to help clinicians learn motivational interviewing. J Consult Clin Psychol. 2004;72(6):1050\u201362.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"15936_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-2850.2009.01187.x","volume":"17","author":"RS Beidas","year":"2010","unstructured":"Beidas RS, Kendall PC. Training therapists in evidence-based practice: A critical review of studies from a systems\u2010contextual perspective. Clin Psychol Sci Pract. 2010;17(1):1\u201330.","journal-title":"Clin Psychol Sci Pract"},{"issue":"1","key":"15936_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12885-019-5289-x","volume":"19","author":"JJ Arch","year":"2019","unstructured":"Arch JJ, Mitchell JL, Genung SR, Fisher R, Andorsky DJ, Stanton AL. A randomized controlled trial of a group acceptance-based intervention for cancer survivors experiencing anxiety at re-entry (\u2018Valued Living\u2019): study protocol. BMC Cancer. 2019;19(1):89.","journal-title":"BMC Cancer"},{"issue":"11","key":"15936_CR43","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol. 2010;63(11):1179\u201394.","journal-title":"J Clin Epidemiol"},{"key":"15936_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jpsychores.2015.12.002","volume":"81","author":"JM Cessna","year":"2016","unstructured":"Cessna JM, Jim HS, Sutton SK, Asvat Y, Small BJ, Salsman JM, Zachariah B, Fishman M, Field T, Fernandez H. Evaluation of the psychometric properties of the PROMIS Cancer Fatigue Short Form with cancer patients. J Psychosom Res. 2016;81:9\u201313.","journal-title":"J Psychosom Res"},{"key":"15936_CR45","unstructured":"de Vree B, van der Werf S, Prins J, Bazelmans E, Vercoulen J, Servaes P, de Vries M, Bleijenberg G. Meetinstrumenten bij chronische vermoeidheid. Gedragstherapie; 2002."},{"issue":"1","key":"15936_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.annonc.2019.09.002","volume":"31","author":"H Poort","year":"2020","unstructured":"Poort H, Peters M, Van Der Graaf W, Nieuwkerk P, Van de Wouw A, Nijhuis-van Der Sanden M, Bleijenberg G, Verhagen C, Knoop H. Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial. Ann Oncol. 2020;31(1):115\u201322.","journal-title":"Ann Oncol"},{"issue":"155","key":"15936_CR47","first-page":"1999","volume":"8","author":"PB Jacobsen","year":"1999","unstructured":"Jacobsen PB, Azzarello LM, Hann DM. Relation of catastrophizing to fatigue severity in women with breast cancer. Cancer Res Ther Control. 1999;8(155):1999\u20131164.","journal-title":"Cancer Res Ther Control"},{"issue":"2","key":"15936_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1037\/0022-006X.72.2.355","volume":"72","author":"PB Jacobsen","year":"2004","unstructured":"Jacobsen PB, Andrykowski MA, Thors CL. Relationship of catastrophizing to fatigue among women receiving treatment for breast cancer. J Consult Clin Psychol. 2004;72(2):355.","journal-title":"J Consult Clin Psychol"},{"issue":"6","key":"15936_CR49","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","volume":"19","author":"K Basen-Engquist","year":"2001","unstructured":"Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001;19(6):1809\u201317.","journal-title":"J Clin Oncol"},{"key":"15936_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"15936_CR51","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jclinepi.2010.11.018","volume":"64","author":"KJ Yost","year":"2011","unstructured":"Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64(5):507\u201316.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"15936_CR52","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-022-06705-1","volume":"195","author":"EE Bright","year":"2022","unstructured":"Bright EE, Genung SR, Stanton AL, Arch JJ. A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy. Breast Cancer Res Treat. 2022;195(3):393\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"15936_CR53","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s10461-010-9799-4","volume":"14","author":"JE Haberer","year":"2010","unstructured":"Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, Bangsberg DR. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340\u20136.","journal-title":"AIDS Behav"},{"issue":"13","key":"15936_CR54","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1097\/QAD.0b013e328363b53f","volume":"27","author":"JE Haberer","year":"2013","unstructured":"Haberer JE, Kiwanuka J, Nansera D, Muzoora C, Hunt PW, So J, O\u2019Donnell M, Siedner M, Martin JN, Bangsberg DR. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27(13):2166\u20138.","journal-title":"AIDS"},{"issue":"1","key":"15936_CR55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12879-018-3080-2","volume":"18","author":"N Bionghi","year":"2018","unstructured":"Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico KR, Friedland G, Orrell C, Padayatchi N, O\u2019Donnell MR. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB\/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infect Dis. 2018;18(1):171.","journal-title":"BMC Infect Dis"},{"key":"15936_CR56","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s10461-010-9799-4","volume":"14","author":"J Haberer","year":"2010","unstructured":"Haberer J, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, Bangsberg DR. Real-Time Adherence Monitoring for HIV Antiretroviral Therapy. AIDS Behav. 2010;14:1340\u20136.","journal-title":"AIDS Behav"},{"issue":"13","key":"15936_CR57","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1097\/QAD.0b013e328363b53f","volume":"27","author":"JE Haberer","year":"2013","unstructured":"Haberer JE, Kiwanuka J, Nansera D, Muzoora C, Hunt PW, So J, O\u2019Donnell M, Siedner M, Martin JN, Bangsberg DR. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27(13):2163\u20138.","journal-title":"AIDS"},{"issue":"1","key":"15936_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-3080-2","volume":"18","author":"N Bionghi","year":"2018","unstructured":"Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O\u2019Donnell MR. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB\/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infect Dis. 2018;18(1):1\u20139.","journal-title":"BMC Infect Dis"},{"key":"15936_CR59","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jcbs.2022.07.002","volume":"25","author":"JJ Arch","year":"2022","unstructured":"Arch JJ, Slivjak ET, Bright EE, Crespi CM, Levin ME, Genung SR, Nealis M, Albright K, Mitchell JL, Sheth AD, et al. Leveraging values to promote adherence to endocrine therapy among breast cancer survivors: A mixed-methods investigation. J Context Behav Sci. 2022;25:122\u20139.","journal-title":"J Context Behav Sci"},{"issue":"3","key":"15936_CR60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.beth.2006.08.003","volume":"38","author":"DM Fresco","year":"2007","unstructured":"Fresco DM, Moore MT, Van Dulmen MHM, Segal ZV, Ma SH, Teasdale JD, Williams JM. Initial psychometric properties of the experiences questionnaire: Validation of a self-report measure of decentering. Behav Ther. 2007;38(3):234\u201346.","journal-title":"Behav Ther"},{"issue":"3","key":"15936_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jcbs.2014.06.001","volume":"3","author":"M Smout","year":"2014","unstructured":"Smout M, Davies M, Burns N, Christie A. Development of the Valuing Questionnaire (VQ). J Context Behav Sci. 2014;3(3):164\u201372.","journal-title":"J Context Behav Sci"},{"issue":"4","key":"15936_CR62","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3758\/BF03206553","volume":"36","author":"KJ Preacher","year":"2004","unstructured":"Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res methods instruments computers. 2004;36(4):717\u201331.","journal-title":"Behav Res methods instruments computers"},{"key":"15936_CR63","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York: Routledge; 1988.","edition":"2"},{"issue":"4","key":"15936_CR64","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/sim.3491","volume":"28","author":"E Vittinghoff","year":"2009","unstructured":"Vittinghoff E, Sen S, McCulloch CE. Sample size calculations for evaluating mediation. Stat Med. 2009;28(4):541\u201357.","journal-title":"Stat Med"},{"key":"15936_CR65","doi-asserted-by":"crossref","unstructured":"Wright AAP, Tavormina H, Schmiege A, Matulonis S, Campos UA, Liu SM, Slivjak JF, Gilmour E, Salinger A, Haggerty A, Arch AF. J.J.: Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue. J Clin Oncol. 2023;41.","DOI":"10.1200\/JCO.2023.41.16_suppl.e24122"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15936-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15936-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15936-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:24:58Z","timestamp":1781645098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15936-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15936"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15936-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dana-Farber Cancer Institute serves as the single IRB overseeing the study (protocol #24\u2013105). Informed consent is obtained from all individuals prior to study enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}